Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | HTR2B | P41595 | 5/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571908 | 1.00 | HTR2C (0.46) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL1043098 | 0.91 | HTR2C (0.43) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL29384288 | 0.91 | HTR2C (0.43) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL11030273 | 0.90 | HTR2C (0.42) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL3727526 | 0.83 | TSHR (0.36) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL24216729 | 0.79 | KDM1A (0.42) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL30409857 | 0.79 | KDM1A (0.42) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL29946544 | 0.79 | NSD2 (0.36) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL11632118 | 0.79 | HTR2C (0.41) | HTR2CHTR2BKDM1AHTR2ASLC6A2 | |
| SCHEMBL26132936 | 0.79 | KDM1A (0.34) | HTR2CHTR2BKDM1AHTR2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102603797-A | Phosphine imide ligand (E)-(2-(diphenyl phosphino) benzylidene) hydrazine as well as synthetic method and application of phosphine imide ligand (E)-(2-(diphenyl phosphino) benzylidene) hydrazine | UNIV NANKAI | 2012-07-25 | — | — | CN | claimed |
| EP-4618974-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240277848-A1 | SURFACE-MODIFIED NANOPARTICLE | KYOTO UNIVERSITY (JP) | 2024-08-22 | — | — | US | disclosed |
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4353680-A1 | SURFACE-MODIFIED NANOPARTICLE | Kyoto University (JP) | 2024-04-17 | — | — | EP | disclosed |
| CN-117460698-A | Surface-modified nanoparticles | 国立大学法人京都大学 | 2024-01-26 | — | — | CN | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| EP-0391451-A1 | Fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-10-10 | — | — | EP | disclosed |
| EP-0387923-A2 | Fungicides | ZENECA LIMITED (GB) | 1990-09-19 | — | — | EP | disclosed |
| US-4892885-A | CARDIOTONICS, DIURETICS | AMERICAN CYANAMID COMPANY | 1990-01-09 | — | — | US | disclosed |
| US-4877801-A | 1-Aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical compositions thereof useful as antifungals | SCHERING CORPORATION (US) | 1989-10-31 | — | — | US | disclosed |
| CN-1032782-A | Bactericide | ICI PLC (GB) | 1989-05-10 | — | — | CN | disclosed |
| EP-0307103-A2 | Fungicides | ZENECA LIMITED (GB) | 1989-03-15 | — | — | EP | disclosed |
| US-4737508-A | 1-aryl-1-(1H-azol-1-ylalkyl)-1,3-dihydroisobenzofurans, related derivatives and pharmaceutical compositions thereof useful as antifungals | SCHERING CORPORATION (US) | 1988-04-12 | — | — | US | disclosed |
| CN-87103623-A | Fungicidal agents | ICI PLC (GB) | 1988-02-24 | — | — | CN | disclosed |
| EP-0242081-A1 | Fungicides | ZENECA LIMITED (GB) | 1987-10-21 | — | — | EP | disclosed |
| US-4532237-A | Treating cardiovascular disorders | MERCK & CO., INC. (US) | 1985-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR2C 4306/4885HTR2B 4262/4885KDM1A 4670/4885 |
| US-20240277848-A1 | SURFACE-MODIFIED NANOPARTICLE | EPCAM, CD63, CD22 | HTR2C 3462/4885HTR2B 1694/4885KDM1A 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.